Tevogen Bio Holdings Inc Dossier - Source-backed chat

Tevogen Bio Holdings Inc

TVGNNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.50

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $6.62Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $43.1M

Shares Outstanding 6.5M diluted

Next Earnings Date16 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Tevogen Bio Holdings Inc. (NASDAQ: TVGN) is a clinical-stage specialty immunotherapy company utilizing its proprietary ExacTcell™ platform to develop off-the-shelf, genetically unmodified precision T-cell therapies. While its lead candidate, TVGN 489, has shown promising proof-of-concept safety and efficacy data for high-risk COVID-19 and Long COVID, the company faces severe liquidity constraints. With only $0.7 million in cash as of March 31, 2026, and a stockholders' deficit of $9.8 million, Tevogen is highly dependent on external financing, related-party loans, and dilutive equity sales to sustain operations. Although management is pursuing strategic acquisitions (such as a CRO and MSO) to diversify revenue and target up to $100 million in annual sales, these transactions remain non-binding and subject to execution risks. Furthermore, the company must resolve Nasdaq listing compliance issues by mid-October 2026. Given the high-risk, pre-revenue nature of the business balanced against its innovative platform and strategic pivots, a Hold recommendation is warranted.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$1.0030%

The bear case materializes if Tevogen fails to secure additional funding, preventing the launch of new clinical trials and stalling the development of TVGN 489. The non-binding acquisition LOIs fall through, leaving the company entirely pre-revenue. Continued cash burn exhausts the remaining capacity of its loan facility, and the company is unable to regain compliance with Nasdaq listing requirements, leading to delisting and severe capital impairment.

Base CaseCentral scenario

$10.4750%

In the base case, Tevogen continues to operate under tight liquidity, relying on its related-party loan facility, ATM equity program, and the $3.0 million PIPE warrant proceeds to fund basic operations. Clinical trial expansion for TVGN 489 remains deferred or progresses slowly until substantial capital is secured. The company successfully regains Nasdaq compliance but experiences delays in closing its proposed acquisitions, keeping revenues at or near zero in the near term while losses gradually narrow.

Bull CaseUpside scenario

$100.0020%

The bull case is driven by the successful initiation and rapid enrollment of TVGN 489 clinical trials for Long COVID, supported by non-dilutive government grants or strategic partnerships. Additionally, the company successfully closes its pending acquisitions of a CRO and MSO, immediately generating over $50 million to $100 million in annual revenue, which stabilizes cash flows and funds the clinical pipeline without heavy shareholder dilution. The Tevogen.AI platform successfully accelerates target identification, leading to high-value out-licensing deals.

Scenarios reflect our research view at the research date.

Key Investment Merits

Proprietary ExacTcell™ platform offering off-the-shelf, genetically unmodified precision T-cell therapies with strong safety profiles.
TVGN 489 proof-of-concept data showing 100% of treated high-risk patients did not develop Long COVID.
Strategic pivot toward revenue-generating acquisitions (CRO, MSO) to build a diversified healthcare enterprise.
Integration of Tevogen.AI in partnership with Microsoft and Databricks to optimize drug discovery and clinical trials.

Key Investment Risks

Severe liquidity constraints with only $0.7 million in cash and a stockholders' deficit of $9.8 million as of Q1 2026.
High dependence on external financing, related-party debt, and dilutive equity issuances to fund operations.
Nasdaq listing compliance risk, with a deadline of mid-October 2026 to resolve market value deficiencies.
Execution and integration risks associated with non-binding strategic acquisitions.

Thesis Invalidation Triggers

Failure to regain compliance with Nasdaq listing requirements, resulting in stock delisting.
Inability to secure the necessary capital to initiate the next clinical phase of TVGN 489.
Termination or failure to close the proposed CRO and MSO acquisitions, preventing near-term revenue generation.
Negative safety or efficacy readouts in future clinical trials of TVGN 489.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.